Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001). This is an ASCO Meeting Abstract from the 2023 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results